CVRdatabase
Menu

Proxi Biotech ApS

Private limited companyCVR 39859211København VActive

Proxi Biotech ApS is a private limited company, based in København V, active in research and experimental development on natural sciences and engineering, founded in 2018. Equity was negative at the end of 2025 (−DKK 1.7m). The company went from a profit in 2024 to a loss of DKK 1.7m in 2025. 6 people are registered in the company's management and ownership.

Follow
PDF reportCompare

Key figures · financial year 2025

Gross profit−DKK 431k−143.8% vs. 2024
Net profit−DKK 1.7m−495.7% vs. 2024
Equity−DKK 1.7m−510.8% vs. 2024
Employees6latest month from CVR

What has changed

calculated from recorded figures and dates

Financials: 2025 against 2024

  • Gross profit fell 144% (2024 → 2025), to −DKK 431k.
  • Net profit went from a profit of DKK 427k to a loss of DKK 1.7m (2024 → 2025).
  • Equity turned negative: −DKK 1.7m (2024 → 2025).

Employees

  • 4 more employees than a year earlier: 6 (07/2026) against 2 (07/2025).

Management and owners, last 24 months

  • New in management: Per Bo Pedersen Fischer (board member, 10/11/2025), Rene Jørgensen (board member, 10/11/2025) and Sten Verland (chair of the board, 10/11/2025) (+2).
  • New owners registered: Aminzadeh Holding ApS (07/01/2025), Dr RJ Holding ApS (22/01/2025) and Century House Holding ApS (22/01/2025) (+4).
  • No longer registered as owner: Aminzadeh Holding ApS (06/01/2025), Dr RJ Holding ApS (21/01/2025) and Rene Jørgensen (21/01/2025) (+3).

Registrations, last 24 months

  • 22/01/2025: Name changed from PrOxi Biotech ApS to Proxi Biotech ApS
  • 01/01/2025: Industry changed to Research and experimental development on natural sciences and engineering (721000)

Calculated from the latest two annual reports in sequence and from registrations in CVR. A figure that is missing in either year gives no line, and we derive no figures.

Financial statements

Financial years 2020–2025 · amounts in DKK thousand

Equity and net profit

−DKK 2m−DKK 1.5m−DKK 1m−DKK 500kDKK 0DKK 500k202020212022202320242025
EquityNet profit
Financial figures for Proxi Biotech ApS
202020212022202320242025Change
Revenuenot statednot statednot statednot statednot statednot stated–
Gross profit337461411521984−431−143.8%
Operating profit (EBIT)976−6082534−1,484−378.1%
Profit before tax852−7269534−2,079−489%
Net profit852−7269427−1,689−495.7%
Total assets477198922196133,048+397.2%
Equity−9−6−79−10417−1,713−510.8%
Liabilities486204171229724,761+6,525.2%
Cash and cash equivalents45017742181232,310+9,817.3%
Average number of employees111112+100%

Source: annual reports filed with the Danish Business Authority (XBRL). Figures for the company (not the group); change is the latest year against the year before. “–” means the figure is not stated in the annual report. Revenue is not stated for 2020, 2021, 2022, 2023, 2024, 2025: smaller companies may omit it, and we do not derive it from other figures.

Download the figures as CSV · free with an account, amounts in whole DKK

−DKK 600k−DKK 400k−DKK 200kDKK 0DKK 200kDKK 400kDKK 600kDKK 800kDKK 1m202020212022202320242025
Gross profitMedian, the industry (431 companies)

Signals from the financial statements

calculated from the 2025 figures

  • Negative equity

    Equity was −DKK 1.7m at the end of 2025.

    How is this calculated?

    Equity in the latest annual report is below zero.

The signals are rules applied to the figures in the annual reports. They are not an assessment or credit rating of the company. See Data and method.

Annual reports

6 financial years
Annual reports for Proxi Biotech ApS
Financial yearPeriodPublishedFigures forDocuments
202501/01/2025 – 31/12/202528/06/2026The companyPDF not statedXBRL
202401/01/2024 – 31/12/202426/06/2025The companyPDFXBRL
202301/01/2023 – 31/12/202323/05/2024The companyPDFXBRL
202201/01/2022 – 31/12/202230/05/2023The companyPDFXBRL
202101/01/2021 – 31/12/202104/04/2022The companyPDFXBRL
202001/01/2020 – 31/12/202013/04/2021The companyPDFXBRL

The figures from all the annual reports are shown on this page. The documents themselves (PDF and XBRL, the machine-readable edition) are downloaded with a Pro account: sign in or create a free account, and then choose Pro. XBRL is the edition the figures on the page are read from.

Employees

monthly figures from CVR
0123456703/2304/2305/2306/2307/2308/2309/2310/2311/2312/2301/2403/2404/2405/2406/2407/2409/2410/2412/2403/2504/2505/2506/2507/2508/2509/2510/2511/2512/2501/2602/2603/2604/2605/2606/2607/26
Employees

Position in the industry

431 companies in the database

Comparison with the other companies in research and experimental development on natural sciences and engineering based on the latest financial year.

Gross profit−DKK 431kNo. 291 of 421
Better than 31% of the companies in the industry
Equity−DKK 1.7mNo. 356 of 431
Better than 17% of the companies in the industry
Number of employees6No. 290 of 431
Better than 33% of the companies in the industry

Industry median: gross profit DKK 616k, net profit −DKK 892k, equity DKK 2m, 5 employees.

DKK 100kDKK 2.5mDKK 63.4mDKK 1.6bnDKK 13.7bn
Distribution of gross profit for 250 companies in the industry (latest financial year, logarithmic scale). Amber bar: where this company sits.

Compared with similar companies

size, age and company form
Rank among similar companies
GroupGross profitEquity
Companies with fewer than 20 employees69,967 companies in the comparison
No. 67,909of 69,742
Better than 3%
No. 68,038of 69,964
Better than 3%
Same industry and fewer than 20 employees329 companies in the comparison
No. 214of 323
Better than 34%
No. 266of 329
Better than 19%
Companies that are between 5 and 14 years old33,688 companies in the comparison
No. 32,851of 33,588
Better than 2%
No. 32,378of 33,687
Better than 4%
All companies of type ApS66,508 companies in the comparison
No. 64,957of 66,379
Better than 2%
No. 64,569of 66,505
Better than 3%

The rank is calculated among companies in the database with a figure for the latest financial year, and is shown only for groups of at least ten companies.

Compare with the industry

Research and experimental development on natural sciences and engineering
Gross profit
  1. Proxi Biotech ApS−DKK 431k
  2. Carlsberg A/SDKK 40.2bn
  3. Zealand Pharma A/SDKK 9.2bn
Net profit
  1. Proxi Biotech ApS−DKK 1.7m
  2. Carlsberg A/SDKK 7bn
  3. Zealand Pharma A/SDKK 6.5bn
Equity
  1. Proxi Biotech ApS−DKK 1.7m
  2. Carlsberg A/SDKK 30.7bn
  3. Zealand Pharma A/SDKK 14.8bn
Employees
  1. Proxi Biotech ApS6
  2. Carlsberg A/S107
  3. Zealand Pharma A/S569

Latest financial year per company. Choose up to three companies from the largest in the industry.

Owners and group

from the Public Ownership Register
Owners
  • Aminzadeh Holding ApS33.33%
  • Dr RJ Holding ApS33.33%
Proxi Biotech ApS

Management

7 active registrations

Executive management

Executive management at Proxi Biotech ApS
NameRoleAppointed
Aria AminzadehDirector06/05/2020
Rene JørgensenCEO10/06/2020

Board of directors

Board of directors at Proxi Biotech ApS
NameRoleAppointed
Per Bo Pedersen FischerBoard member10/11/2025
Rene JørgensenBoard member10/11/2025
Sten VerlandChair of the board10/11/2025
Aria AminzadehBoard member10/11/2025
Paul Jefferson HargreavesBoard member10/11/2025
Founders
Gubba Holding ApS
Former management (3)
Former management at Proxi Biotech ApS
NameRoleAppointedResigned
Kasper Gubba ØrtenbladCEO13/09/201809/06/2020
Rene JørgensenDirector06/05/202009/06/2020
Kasper Gubba ØrtenbladDirector10/06/202029/11/2020

Signing rule: Selskabet tegnes af et medlem af direktionen eller af den samlede bestyrelse i forening.

Address and production units

1 active production units

Skjalm Hvides Gade 12
1728 København V

København Municipality · Postcode 1728

Production units
Production unitAddressEmployeesP number
Proxi Biotech ApSSkjalm Hvides Gade 12, 3. th, 1728 København V71023951394

Purpose

Selskabets formål er at udøve forskning og eksperimentel udvikling indenfor bioteknologi

The purpose is quoted from the register in Danish.

Changes year by year

49 registered events
20261 changeaccounts 1
  • Annual report for 2025 published
202521 changesmanagement 5 · accounts 1 · name 1 · ownership 13 · industry 1
  • Paul Jefferson Hargreaves appointed board member
  • Per Bo Pedersen Fischer appointed board member
  • Rene Jørgensen appointed board member
  • Sten Verland appointed chair of the board
  • Aria Aminzadeh appointed board member
  • Annual report for 2024 published
  • Name changed from PrOxi Biotech ApS to Proxi Biotech ApS
  • Rene Jørgensen registered as owner (33.33%)
  • Rene Jørgensen is no longer registered as owner
  • Century House Holding ApS registered as owner (0%)
  • Dr RJ Holding ApS registered as owner (33.33%)
  • Aria Aminzadeh registered as owner (33.33%)
  • Aria Aminzadeh is no longer registered as owner
  • Aria Aminzadeh is no longer registered as owner
  • Rene Jørgensen is no longer registered as owner
  • Dr RJ Holding ApS is no longer registered as owner
  • Aria Aminzadeh registered as owner (33.33%)
  • Rene Jørgensen registered as owner (50%)
  • Aminzadeh Holding ApS registered as owner (33.33%)
  • Aminzadeh Holding ApS is no longer registered as owner
  • Industry changed to Research and experimental development on natural sciences and engineering (721000)
20242 changesaddress 1 · accounts 1
  • Moved to Skjalm Hvides Gade 12, 3. th, 1728 København V
  • Annual report for 2023 published
20231 changeaccounts 1
  • Annual report for 2022 published
20221 changeaccounts 1
  • Annual report for 2021 published
20212 changesaddress 1 · accounts 1
  • Moved to Egeskellet 6, 2000 Frederiksberg
  • Annual report for 2020 published
202012 changesmanagement 7 · ownership 5
  • Kasper Gubba Ørtenblad stepped down as director
  • Dr RJ Holding ApS registered as owner (50%)
  • Aminzadeh Holding ApS registered as owner (50%)
  • Gubba Holding ApS is no longer registered as owner
  • Aminzadeh Holding ApS is no longer registered as owner
  • Dr RJ Holding ApS is no longer registered as owner
  • Kasper Gubba Ørtenblad appointed director
  • Rene Jørgensen appointed ceo
  • Rene Jørgensen stepped down as director
  • Kasper Gubba Ørtenblad stepped down as ceo
  • Rene Jørgensen appointed director
  • Aria Aminzadeh appointed director
20196 changesname 1 · capital 2 · address 1 · ownership 2
  • Name changed from PrOxi Biotech IVS to PrOxi Biotech ApS
  • Share capital changed from 100 DKK to 40,000 DKK
  • Moved to Nørre Allé 41, 2200 København N
  • Share capital changed from 1 DKK to 100 DKK
  • Aminzadeh Holding ApS registered as owner (33.33%)
  • Dr RJ Holding ApS registered as owner (33.33%)
20183 changesfounded 1 · management 1 · ownership 1
  • Registered as PrOxi Biotech IVS
  • Kasper Gubba Ørtenblad appointed ceo
  • Gubba Holding ApS registered as owner (25%)

Related companies

Same industry in København

See all →

Same people in management

Largest in the industry

See all →

Source and updates

The information comes from the Danish Central Business Register (Danish Business Authority) and from annual reports filed with the Danish Business Authority. Last synchronised 24/10/2026. The company is protected against advertising; contact details are not shown, and the data must not be used for marketing.

View in CVRReport a correction